Alterity Therapeutics to Present at the 34 th Annual Roth Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnolo

Therapeutics to Present at the 34th Annual Roth Conference

AUSTRALIA AND SAN FRANCISCO, USA - 7 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or

"the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,

today announced that David Stamler, M.D., Chief Executive Officer will present a company update and participate in investor meetings

at the 34th Annual Roth Conference.

conference is taking place Monday, 14 March and Tuesday, 15 March 2022 in Dana Point, California, USA.

Roth presentation recording is accessible now on the Alterity website under News.

Alterity Therapeutics Limited

Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative

diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad

drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne,

Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

& Additional information

announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.